485 related articles for article (PubMed ID: 31932695)
1. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
2. ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan S; Rao SV; Sutton J; Cheeseman D; Dunn S; Papachristou EK; Prada JG; Couturier DL; Kumar S; Kishore K; Chilamakuri CSR; Glont SE; Archer Goode E; Brodie C; Guppy N; Natrajan R; Bruna A; Caldas C; Russell A; Siersbæk R; Yusa K; Chernukhin I; Carroll JS
Nat Genet; 2020 Feb; 52(2):187-197. PubMed ID: 31913353
[TBL] [Abstract][Full Text] [Related]
3. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
4. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.
Fu X; Huang C; Schiff R
Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280
[TBL] [Abstract][Full Text] [Related]
5. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
7. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER
Gawrzak S; Rinaldi L; Gregorio S; Arenas EJ; Salvador F; Urosevic J; Figueras-Puig C; Rojo F; Del Barco Barrantes I; Cejalvo JM; Palafox M; Guiu M; Berenguer-Llergo A; Symeonidi A; Bellmunt A; Kalafatovic D; Arnal-Estapé A; Fernández E; Müllauer B; Groeneveld R; Slobodnyuk K; Stephan-Otto Attolini C; Saura C; Arribas J; Cortes J; Rovira A; Muñoz M; Lluch A; Serra V; Albanell J; Prat A; Nebreda AR; Benitah SA; Gomis RR
Nat Cell Biol; 2018 Feb; 20(2):211-221. PubMed ID: 29358704
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
10. ELF5 modulates the estrogen receptor cistrome in breast cancer.
Piggin CL; Roden DL; Law AMK; Molloy MP; Krisp C; Swarbrick A; Naylor MJ; Kalyuga M; Kaplan W; Oakes SR; Gallego-Ortega D; Clark SJ; Carroll JS; Bartonicek N; Ormandy CJ
PLoS Genet; 2020 Jan; 16(1):e1008531. PubMed ID: 31895944
[TBL] [Abstract][Full Text] [Related]
11. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.
van Bragt MP; Hu X; Xie Y; Li Z
Elife; 2014 Nov; 3():e03881. PubMed ID: 25415051
[TBL] [Abstract][Full Text] [Related]
12. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
14. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
15. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
17. ARID1A-dependent permissive chromatin accessibility licenses estrogen-receptor signaling to regulate circadian rhythms genes in endometrial cancer.
Hu H; Chen Z; Ji L; Wang Y; Yang M; Lai R; Zhong Y; Zhang X; Wang L
Cancer Lett; 2020 Nov; 492():162-173. PubMed ID: 32858102
[TBL] [Abstract][Full Text] [Related]
18. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
19. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
Giessrigl B; Schmidt WM; Kalipciyan M; Jeitler M; Bilban M; Gollinger M; Krieger S; Jäger W; Mader RM; Krupitza G
Br J Cancer; 2013 Nov; 109(10):2751-62. PubMed ID: 24169358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
